GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • International Union Against Tuberculosis and Lung Disease  (9)
Material
Publisher
  • International Union Against Tuberculosis and Lung Disease  (9)
Person/Organisation
Language
Years
  • 1
    Online Resource
    Online Resource
    TB and COVID-19 co-infection: rationale and aims of a global study
    International Union Against Tuberculosis and Lung Disease ; 2021
    In:  The International Journal of Tuberculosis and Lung Disease Vol. 25, No. 1 ( 2021-01-01), p. 78-80
    Details
    In: The International Journal of Tuberculosis and Lung Disease, International Union Against Tuberculosis and Lung Disease, Vol. 25, No. 1 ( 2021-01-01), p. 78-80
    Type of Medium: Online Resource
    ISSN: 1027-3719
    URL: Article
    DOI: 10.5588/ijtld.20.0786
    Language: English
    Publisher: International Union Against Tuberculosis and Lung Disease
    Publication Date: 2021
    detail.hit.zdb_id: 2168620-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Clinical standards for the management of adverse effects during treatment for TB
    International Union Against Tuberculosis and Lung Disease ; 2023
    In:  The International Journal of Tuberculosis and Lung Disease Vol. 27, No. 7 ( 2023-07-01), p. 506-519
    Details
    In: The International Journal of Tuberculosis and Lung Disease, International Union Against Tuberculosis and Lung Disease, Vol. 27, No. 7 ( 2023-07-01), p. 506-519
    Abstract: BACKGROUND: Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE. METHODS: 65/81 invited experts participated in a Delphi process using a 5-point Likert scale to score draft standards. RESULTS: We identified eight clinical standards. Each person commencing treatment for TB should: Standard 1, be counselled regarding AE before and during treatment; Standard 2, be evaluated for factors that might increase AE risk with regular review to actively identify and manage these; Standard 3, when AE occur, carefully assessed and possible allergic or hypersensitivity reactions considered; Standard 4, receive appropriate care to minimise morbidity and mortality associated with AE; Standard 5, be restarted on TB drugs after a serious AE according to a standardised protocol that includes active drug safety monitoring. In addition: Standard 6, healthcare workers should be trained on AE including how to counsel people undertaking TB treatment, as well as active AE monitoring and management; Standard 7, there should be active AE monitoring and reporting for all new TB drugs and regimens; and Standard 8, knowledge gaps identified from active AE monitoring should be systematically addressed through clinical research. CONCLUSION: These standards provide a person-centred, consensus-based approach to minimise the impact of AE during TB treatment.
    Type of Medium: Online Resource
    ISSN: 1027-3719
    URL: Article
    DOI: 10.5588/ijtld.23.0078
    Language: English
    Publisher: International Union Against Tuberculosis and Lung Disease
    Publication Date: 2023
    detail.hit.zdb_id: 2168620-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Clinical standards for the assessment, management and rehabilitation of post-TB lung disease
    International Union Against Tuberculosis and Lung Disease ; 2021
    In:  The International Journal of Tuberculosis and Lung Disease Vol. 25, No. 10 ( 2021-10-01), p. 797-813
    Details
    In: The International Journal of Tuberculosis and Lung Disease, International Union Against Tuberculosis and Lung Disease, Vol. 25, No. 10 ( 2021-10-01), p. 797-813
    Abstract: BACKGROUND: Increasing evidence suggests that post-TB lung disease (PTLD) causes significant morbidity and mortality. The aim of these clinical standards is to provide guidance on the assessment and management of PTLD and the implementation of pulmonary rehabilitation (PR). METHODS: A panel of global experts in the field of TB care and PR was identified; 62 participated in a Delphi process. A 5-point Likert scale was used to score the initial ideas for standards and after several rounds of revision the document was approved (with 100% agreement). RESULTS: Five clinical standards were defined: Standard 1, to assess patients at the end of TB treatment for PTLD (with adaptation for children and specific settings/situations); Standard 2, to identify patients with PTLD for PR; Standard 3, tailoring the PR programme to patient needs and the local setting; Standard 4, to evaluate the effectiveness of PR; and Standard 5, to conduct education and counselling. Standard 6 addresses public health aspects of PTLD and outcomes due to PR. CONCLUSION: This is the first consensus-based set of Clinical Standards for PTLD. Our aim is to improve patient care and quality of life by guiding clinicians, programme managers and public health officers in planning and implementing adequate measures to assess and manage PTLD.
    Type of Medium: Online Resource
    ISSN: 1027-3719
    URL: Article
    DOI: 10.5588/ijtld.21.0425
    Language: English
    Publisher: International Union Against Tuberculosis and Lung Disease
    Publication Date: 2021
    detail.hit.zdb_id: 2168620-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Clinical standards for the dosing and management of TB drugs
    International Union Against Tuberculosis and Lung Disease ; 2022
    In:  The International Journal of Tuberculosis and Lung Disease Vol. 26, No. 6 ( 2022-06-01), p. 483-499
    Details
    In: The International Journal of Tuberculosis and Lung Disease, International Union Against Tuberculosis and Lung Disease, Vol. 26, No. 6 ( 2022-06-01), p. 483-499
    Abstract: BACKGROUND: Optimal drug dosing is important to ensure adequate response to treatment, prevent development of drug resistance and reduce drug toxicity. The aim of these clinical standards is to provide guidance on ‘best practice´ for dosing and management of TB drugs. METHODS: A panel of 57 global experts in the fields of microbiology, pharmacology and TB care were identified; 51 participated in a Delphi process. A 5-point Likert scale was used to score draft standards. The final document represents the broad consensus and was approved by all participants. RESULTS: Six clinical standards were defined: Standard 1, defining the most appropriate initial dose for TB treatment; Standard 2, identifying patients who may be at risk of sub-optimal drug exposure; Standard 3, identifying patients at risk of developing drug-related toxicity and how best to manage this risk; Standard 4, identifying patients who can benefit from therapeutic drug monitoring (TDM); Standard 5, highlighting education and counselling that should be provided to people initiating TB treatment; and Standard 6, providing essential education for healthcare professionals. In addition, consensus research priorities were identified. CONCLUSION: This is the first consensus-based Clinical Standards for the dosing and management of TB drugs to guide clinicians and programme managers in planning and implementation of locally appropriate measures for optimal person-centred treatment to improve patient care.
    Type of Medium: Online Resource
    ISSN: 1027-3719
    URL: Article
    DOI: 10.5588/ijtld.22.0188
    Language: English
    Publisher: International Union Against Tuberculosis and Lung Disease
    Publication Date: 2022
    detail.hit.zdb_id: 2168620-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Clinical standards for drug-susceptible pulmonary TB
    International Union Against Tuberculosis and Lung Disease ; 2022
    In:  The International Journal of Tuberculosis and Lung Disease Vol. 26, No. 7 ( 2022-07-01), p. 592-604
    Details
    In: The International Journal of Tuberculosis and Lung Disease, International Union Against Tuberculosis and Lung Disease, Vol. 26, No. 7 ( 2022-07-01), p. 592-604
    Abstract: BACKGROUND: The aim of these clinical standards is to provide guidance on ‘best practice´ for diagnosis, treatment and management of drug-susceptible pulmonary TB (PTB). METHODS: A panel of 54 global experts in the field of TB care, public health, microbiology, and pharmacology were identified; 46 participated in a Delphi process. A 5-point Likert scale was used to score draft standards. The final document represents the broad consensus and was approved by all 46 participants. RESULTS: Seven clinical standards were defined: Standard 1, all patients (adult or child) who have symptoms and signs compatible with PTB should undergo investigations to reach a diagnosis; Standard 2, adequate bacteriological tests should be conducted to exclude drug-resistant TB; Standard 3, an appropriate regimen recommended by WHO and national guidelines for the treatment of PTB should be identified; Standard 4, health education and counselling should be provided for each patient starting treatment; Standard 5, treatment monitoring should be conducted to assess adherence, follow patient progress, identify and manage adverse events, and detect development of resistance; Standard 6, a recommended series of patient examinations should be performed at the end of treatment; Standard 7, necessary public health actions sho uld be conducted for each patient. We also identified priorities for future research into PTB. CONCLUSION: These consensus-based clinical standards will help to improve patient care by guiding clinicians and programme managers in planning and implementation of locally appropriate measures for optimal person-centred treatment for PTB.
    Type of Medium: Online Resource
    ISSN: 1027-3719
    URL: Article
    DOI: 10.5588/ijtld.22.0228
    Language: English
    Publisher: International Union Against Tuberculosis and Lung Disease
    Publication Date: 2022
    detail.hit.zdb_id: 2168620-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Clinical standards for the diagnosis, treatment and prevention of TB infection
    International Union Against Tuberculosis and Lung Disease ; 2022
    In:  The International Journal of Tuberculosis and Lung Disease Vol. 26, No. 3 ( 2022-03-01), p. 190-205
    Details
    In: The International Journal of Tuberculosis and Lung Disease, International Union Against Tuberculosis and Lung Disease, Vol. 26, No. 3 ( 2022-03-01), p. 190-205
    Abstract: BACKGROUND: Tuberculosis (TB) preventive therapy (TPT) decreases the risk of developing TB disease and its associated morbidity and mortality. The aim of these clinical standards is to guide the assessment, management of TB infection (TBI) and implementation of TPT. METHODS: A panel of global experts in the field of TB care was identified; 41 participated in a Delphi process. A 5-point Likert scale was used to score the initial standards. After rounds of revision, the document was approved with 100% agreement. RESULTS: Eight clinical standards were defined: Standard 1, all individuals belonging to at-risk groups for TB should undergo testing for TBI; Standard 2, all individual candidates for TPT (including caregivers of children) should undergo a counselling/health education session; Standard 3, testing for TBI: timing and test of choice should be optimised; Standard 4, TB disease should be excluded prior to initiation of TPT; Standard 5, all candidates for TPT should undergo a set of baseline examinations; Standard 6, all individuals initiating TPT should receive one of the recommended regimens; Standard 7, all individuals who have started TPT should be monitored; Standard 8, a TBI screening and testing register should be kept to inform the cascade of care. CONCLUSION: This is the first consensus-based set of Clinical Standards for TBI. This document guides clinicians, programme managers and public health officers in planning and implementing adequate measures to assess and manage TBI.
    Type of Medium: Online Resource
    ISSN: 1027-3719
    URL: Article
    DOI: 10.5588/ijtld.21.0753
    Language: English
    Publisher: International Union Against Tuberculosis and Lung Disease
    Publication Date: 2022
    detail.hit.zdb_id: 2168620-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    A systematic review of the costs of diagnosis for multidrug-resistant/extensively drug-resistant TB in different settings
    International Union Against Tuberculosis and Lung Disease ; 2023
    In:  The International Journal of Tuberculosis and Lung Disease Vol. 27, No. 5 ( 2023-05-01), p. 348-356
    Details
    In: The International Journal of Tuberculosis and Lung Disease, International Union Against Tuberculosis and Lung Disease, Vol. 27, No. 5 ( 2023-05-01), p. 348-356
    Abstract: BACKGROUND: We performed an analysis of the cost and relative merits of different strategies for the diagnosis of multidrug-resistant/extensively drug-resistant TB (MDR/XDR-TB) in different settings. METHODS: We systematically reviewed the published evidence on cost/cost-effectiveness of rapid MDR/pre-XDR-TB and other methods for XDR-TB testing up to September 2022. PRISMA guidelines were followed. Collected data were analysed using Stata v17 software. Cost data were reported in USD ($) and summarised by mean, standard deviation, and range. Country income level was defined according to the World Bank country classification. Three simplified scenarios were also used to explore testing implications, based on low, intermediate and high TB incidence. RESULTS: Of 157 records, 25 studies were included with 24 reporting the cost of Xpert/RIF and two that evaluated the implementation of the MTBDR plus test. The total rapid test cost ranged from $12.41–$218, including $1.13–$74.60 for reagents/consumables and $0.40–$14.34 for equipment. CONCLUSION: The cost of MDR/XDR-TB diagnostics is lower in low resource settings. However, the cost-effective implementation of MDR/XDR-TB diagnostic algorithms requires careful consideration of local resources to avoid missed identification and the use of inappropriate regimen.
    Type of Medium: Online Resource
    ISSN: 1027-3719
    URL: Article
    DOI: 10.5588/ijtld.22.0657
    Language: English
    Publisher: International Union Against Tuberculosis and Lung Disease
    Publication Date: 2023
    detail.hit.zdb_id: 2168620-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Planning for TB elimination in Lebanon
    International Union Against Tuberculosis and Lung Disease ; 2023
    In:  The International Journal of Tuberculosis and Lung Disease Vol. 27, No. 3 ( 2023-03-01), p. 171-174
    Details
    In: The International Journal of Tuberculosis and Lung Disease, International Union Against Tuberculosis and Lung Disease, Vol. 27, No. 3 ( 2023-03-01), p. 171-174
    Type of Medium: Online Resource
    ISSN: 1027-3719
    URL: Article
    DOI: 10.5588/ijtld.22.0673
    Language: English
    Publisher: International Union Against Tuberculosis and Lung Disease
    Publication Date: 2023
    detail.hit.zdb_id: 2168620-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Post-TB disease: a new topic for investigation—and why it matters
    International Union Against Tuberculosis and Lung Disease ; 2021
    In:  The International Journal of Tuberculosis and Lung Disease Vol. 25, No. 4 ( 2021-04-01), p. 258-261
    Details
    In: The International Journal of Tuberculosis and Lung Disease, International Union Against Tuberculosis and Lung Disease, Vol. 25, No. 4 ( 2021-04-01), p. 258-261
    Type of Medium: Online Resource
    ISSN: 1027-3719
    URL: Article
    DOI: 10.5588/ijtld.21.0040
    Language: English
    Publisher: International Union Against Tuberculosis and Lung Disease
    Publication Date: 2021
    detail.hit.zdb_id: 2168620-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...